Statin treatment for patients with paroxysmal atrial fibrillation A J-RHYTHM substudy

International Heart Journal

Volumn 52, Issue 2, 2011, Pages 103-106

  Watanabe, Eiichi ^a   Yamashita, Takeshi ^b   Suzuki, Shinya ^c   Saikawa, Tetsunori ^d   Hirai, Makoto ^e   Yamazaki, Tsutomu ^c   Ohtsu, Hiroshi ^f   Ogawa, Satoshi ^g  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b THE CARDIOVASCULAR INSTITUTE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d OITA UNIVERSITY   (Japan)

^e NAGOYA UNIVERSITY   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Arrhythmia; Dyslipidemia; Mortality; Recurrence

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART PROTECTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RISK REDUCTION; TOTAL QUALITY MANAGEMENT;

AGED; ATRIAL FIBRILLATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 79954496028     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.103     Document Type: Article

References (30)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
2. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow- Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1509-13.
3. Yamashita T, Sekiguchi A, Iwasaki YK, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262-70.
4. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104: 174-80.
5. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108: 346-53.
6. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118. (Review)
7. Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med 2008; 5: 30-41. (Review)
8. Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110: 2313-9.
9. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-11.
10. Shiroshita-Takeshita A, Brundel BJ, Burstein B, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007; 74: 75-84.
11. Ramani G, Zahid M, Good CB, Macioce A, Sonel AF. Comparison of frequency of new-onset atrial fibrillation or flutter in patients on statins versus not on statins presenting with suspected acute coronary syndrome. Am J Cardiol 2007; 100: 404-5.
12. Hanna IR, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006; 3: 881-6.
13. Maggioni AP, Fabbri G, Lucci D, et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 2009; 30: 2327-36.
14. Dernellis J, Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 2005; 150: 1064.
15. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006; 114: 1455-61.
16. Ozaydin M, Dogan A, Varol E, et al. Statin use before by-pass surgery decreases the incidence and shortens the duration of postoperative atrial fibrillation. Cardiology 2007; 107: 117-21.
17. Tsai CT, Lai LP, Hwang JJ, Wang YC, Chiang FT, Lin JL. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial. Am Heart J 2008; 156: 65-70.
18. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008; 51: 828-35.
19. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008; 126: 160-70. (Review)
20. Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73: 242-8.
21. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 2003; 92: 1379-83.
22. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2004; 93: 780-2.
23. Hirayama Y, Atarashi H, Kobayashi Y, et al. Long-term effects of upstream therapy on paroxysmal atrial fibrillation in patients without overt heart diseases. Int Heart J 2009; 50: 141-51.
24. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54: 2023-31.
25. Marín F, Pascual DA, Roldán V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 2006; 97: 55-60.
26. Kourliouros A, De Souza A, Roberts N, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008; 85: 1515-20.
27. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005; 112: 1428-34.
28. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999; 100: 87-95.
29. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104: 2608-14.
30. Turner NA, Midgley L, O'Regan DJ, Porter KE. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 2007; 50: 458-61.